A comprehensive acute coronary syndrome algorithm for centers with percutaneous coronary intervention capability.
暂无分享,去创建一个
Michael C. McDaniel | Corinne R. Fantz | A. Finn | A. Goyal | H. Liberman | D. Morris | H. Samady | M. Keadey | S. T. Rab | M. Ross | K. Mavromatis | C. Fantz | A. Osborne | A. Winkler | D. Lowery-North | Abhinav Goyal | M. McDaniel
[1] Sunil V. Rao,et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. , 2012, Journal of the American College of Cardiology.
[2] E. Romagnoli,et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. , 2012, Journal of the American College of Cardiology.
[3] V. Hertzberg,et al. Ability of triage decision rules for rapid electrocardiogram to identify patients with suspected ST-elevation myocardial infarction. , 2012, Critical pathways in cardiology.
[4] N. Schork,et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. , 2012, Journal of the American College of Cardiology.
[5] Michael C Wu,et al. Development and validation of a prioritization rule for obtaining an immediate 12-lead electrocardiogram in the emergency department to identify ST-elevation myocardial infarction. , 2012, American heart journal.
[6] Robert J Brison,et al. Development of a clinical prediction rule for 30-day cardiac events in emergency department patients with chest pain and possible acute coronary syndrome. , 2012, Annals of emergency medicine.
[7] Laura Mauri,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.
[8] Jörg Hausleiter,et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. , 2011, The New England journal of medicine.
[9] M. Price,et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. , 2011, Journal of the American College of Cardiology.
[10] P. Teirstein,et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial , 2011, Circulation.
[11] C. Held,et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. , 2011, Circulation.
[12] B. Gersh,et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial , 2011, The Lancet.
[13] G. Stone,et al. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction , 2011, Circulation.
[14] Sunil V. Rao,et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial , 2011, The Lancet.
[15] E. Antman,et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.
[16] E. Antman,et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis , 2010, The Lancet.
[17] B. J. Barratt,et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial , 2010, The Lancet.
[18] A. Bavry,et al. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. , 2010, Journal of the American College of Cardiology.
[19] J. Horowitz,et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19‐genotyped subgroups: integration of the TRITON‐TIMI 38 trial data , 2010, Journal of thrombosis and haemostasis : JTH.
[20] M. Galvani,et al. Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. , 2010, The American journal of cardiology.
[21] Stefan Blankenberg,et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. , 2009, The New England journal of medicine.
[22] Tobias Reichlin,et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. , 2009, The New England journal of medicine.
[23] M. Sabatine,et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. , 2009, Journal of the American College of Cardiology.
[24] R. Califf,et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.
[25] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[26] G. De Luca,et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. , 2009, Journal of the American College of Cardiology.
[27] H. Gurm,et al. A Comparison of Abciximab and Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention: A Meta-Analysis of Contemporary Randomized Controlled Trials , 2009, Circulation. Cardiovascular interventions.
[28] A. Kastrati,et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. , 2008, The New England journal of medicine.
[29] B. Gersh,et al. Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.
[30] F. Prati,et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. , 2008, JAMA.
[31] Matthew J Price,et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. , 2008, European heart journal.
[32] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[33] E. Antman,et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. , 2007, European heart journal.
[34] Michail I. Papafaklis,et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. , 2007, Journal of the American College of Cardiology.
[35] D. Moliterno,et al. Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study. , 2007, American heart journal.
[36] V. Pasceri,et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. , 2007, Journal of the American College of Cardiology.
[37] J. Ware,et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. , 2007, JAMA.
[38] Adelaide,et al. Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.
[39] Elizabeth R DeLong,et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. , 2006, JAMA.
[40] A. Kastrati,et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.
[41] F. Sozzi,et al. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. , 2006, The American journal of cardiology.
[42] S. Yusuf,et al. Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes , 2003, Circulation.
[43] James E. Calvin,et al. Impact of a Clinical Decision Rule on Hospital Triage of Patients With Suspected Acute Cardiac Ischemia in the Emergency Department , 2002 .
[44] B. Sobel,et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. , 2002, The American journal of cardiology.
[45] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[46] E. Topol,et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.
[47] S. Wolf,et al. Triage of patients for a rapid (5-minute) electrocardiogram: A rule based on presenting chief complaints. , 2000, Annals of emergency medicine.
[48] E. Antman,et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.
[49] Robert Woolard,et al. Missed Diagnoses of Acute Cardiac Ischemia in the Emergency Department , 2000 .
[50] A R Zinsmeister,et al. A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators. , 1998, The New England journal of medicine.
[51] R. Roberts,et al. Costs of an emergency department-based accelerated diagnostic protocol vs hospitalization in patients with chest pain: a randomized controlled trial. , 1997, JAMA.
[52] L. Graff,et al. Impact on the care of the emergency department chest pain patient from the chest pain evaluation registry (CHEPER) study. , 1997, The American journal of cardiology.
[53] R. Roberts,et al. Patient satisfaction with an emergency department chest pain observation unit. , 1997, Annals of emergency medicine.
[54] E F Cook,et al. Prediction of the need for intensive care in patients who come to emergency departments with acute chest pain. , 1996, The New England journal of medicine.